Moderna Rallies on Quick Coronavirus Vaccine Turnaround
- Shares are up as much as 25% in pre-market trading on Tuesday
- Experimental vaccine shipped for use in clinical trial
This article is for subscribers only.
In less than two months since the genetic makeup of the novel coronavirus was first sequenced, Moderna Inc. has shipped its first vaccine for testing in humans.
The experimental vaccine has been sent to the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, for use in the first stage of a clinical trial. The agency could be ready to test Moderna’s vaccine by late April, NIAID Director Anthony S. Fauci said in January.